



August 1, 2020

**Re: Anthem prior authorization updates for specialty pharmacy are available**

Dear Provider:

Anthem Blue Cross and Blue Shield and our subsidiary company, HMO Nevada (Anthem), is writing to inform you of the following updates to the AIM Specialty Health® (AIM) Clinical Criteria and prior authorization requirements. AIM is a separate company.

**Quantity limit updates**

Effective for dates of service on and after November 1, 2020, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our existing prior authorization quantity limit review process.

To access the Clinical Criteria information please click [here](https://www11.anthem.com/pharmacyinformation/clinicalcriteria.html). (Or go directly to URL: <https://www11.anthem.com/pharmacyinformation/clinicalcriteria.html>)

Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team.

Clinical Criteria	HCPCS or CPT Code(s)	Drug
ING-CC-0044	J1428	Exondys 51
ING-CC-0058	J2354	Bynfezia
ING-CC-0072	J0179	Beovu
ING-CC-0075	Q5119	Ruxience
ING-CC-0152	J1429	Vyondys 53
ING-CC-0153	C9053	Adakveo

**Clinical criteria updates**

Effective for dates of service on and after November 1, 2020, the following clinical criteria document was revised and might result in services that were previously covered but may now be found to be not medically necessary in our prior authorization review process.

To access the Clinical Criteria information, please click [here](https://www11.anthem.com/pharmacyinformation/clinicalcriteria.html). (Or go directly to URL: <https://www11.anthem.com/pharmacyinformation/clinicalcriteria.html>)

Anthem's prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem's medical specialty drug review team.

- **ING-CC-0003 Immunoglobulins**


Updated medical necessity criteria for myasthenia gravis to include specific drug failures and chronic inflammatory demyelinating polyneuropathy to include requirements regarding disease duration, specific electrodiagnostic criterion, and objective measures for continuation.

In the May 2020 edition of *Provider News*, we published a prior authorization update regarding clinical criteria **ING-CC-0157** on the drug Padcev.

- One HCPCS code, J9309, was listed in error. This is not a valid code for the drug Padcev.
- One HCPCS code has been added, J9999. This is a valid code for the drug Padcev.

We value and appreciate you as our partner in providing quality care, and appreciate your continued participation in our network.

Sincerely,



Jo Ann Nishimoto, MD  
Medical Director  
Anthem Blue Cross and Blue Shield